Dravet Syndrome Clinical Trial
Official title:
An Open-Label Extension Trial to Assess the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution as an Adjunctive Therapy for Seizures in Patients With Rare Seizure Disorders Such as Epileptic Encephalopathies Including Dravet Syndrome and Lennox-Gastaut Syndrome
This is an international, multicenter, open-label, long-term safety study of ZX008 in subjects with Dravet syndrome, Lennox-Gastaut syndrome or epileptic encephalopathy
This is an international, multicenter, open-label, long-term safety study of ZX008 in patients with epileptic encephalopathy, including Dravet syndrome or Lennox-Gastaut syndrome. Subjects eligible for participation are those with Dravet syndrome who are currently enrolled in Study ZX008-1503, or those with Lennox-Gastaut syndrome who have successfully completed Study ZX008-1601-Part 2, and are candidates for continued treatment with ZX008 for an extended period of time, or those with Dravet syndrome, Lennox-Gastaut syndrome, or another epileptic encephalopathy who have completed participation in another Zogenix-sponsored study and have been invited to participate in this study. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05651204 -
GABA Biomarkers in Dravet Syndrome
|
||
| Withdrawn |
NCT02910297 -
The Pharmacokinetics of Cannabidiol (CBD) and Its Effects in Children With Severe Epilepsy
|
||
| Recruiting |
NCT04462770 -
EPX-100 (Clemizole Hydrochloride) as Add-on Therapy to Control Convulsive Seizures in Patients With Dravet Syndrome
|
Phase 2 | |
| Completed |
NCT02896608 -
Neuronal Excitability of HCN1 Channel Mutations in Dravet Syndrome
|
||
| Withdrawn |
NCT05140122 -
LEONIDaS Caregivers Study
|
||
| Recruiting |
NCT05635266 -
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
|
||
| Completed |
NCT02091206 -
A Dose-ranging Pharmacokinetics and Safety Study of GWP42003-P in Children With Dravet Syndrome (GWPCARE1)
|
Phase 2 | |
| Enrolling by invitation |
NCT03655223 -
Early Check: Expanded Screening in Newborns
|
||
| Recruiting |
NCT05472389 -
Neurodevelopmental Impact of Epilepsy on Autonomic Function in Dravet Syndrome
|
N/A | |
| Active, not recruiting |
NCT05626634 -
Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic Encephalopathy
|
Phase 2 | |
| Recruiting |
NCT01858285 -
Genetics of Epilepsy and Related Disorders
|
||
| Recruiting |
NCT04614506 -
Transcranial Magnetic Stimulation to Measure Cortical Excitability in Dravet Syndrome
|
||
| Recruiting |
NCT06118255 -
A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Fenfluramine (Hydrochloride) in Infants 1 Year to Less Than 2 Years of Age With Dravet Syndrome
|
Phase 3 | |
| Recruiting |
NCT04611438 -
Research on Cognitive Effect of Cannabidiol on Dravet Syndrome and Lennox-Gastaut SyndromeGastaut Syndrome
|
Phase 3 | |
| Completed |
NCT02091375 -
Antiepileptic Efficacy Study of GWP42003-P in Children and Young Adults With Dravet Syndrome (GWPCARE1)
|
Phase 3 | |
| Completed |
NCT05364021 -
Study to Investigate LP352 in Subjects With Developmental and Epileptic Encephalopathies
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06112275 -
A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Children With SCN1A-positive Dravet Syndrome (Australia Only)
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT03254680 -
Turmeric as Treatment in Epilepsy
|
N/A | |
| Withdrawn |
NCT02174094 -
Clobazam as Adjunctive Therapy in Paediatric Patients Aged ≥1 to ≤16 Years With Dravet Syndrome
|
Phase 3 | |
| Terminated |
NCT02187809 -
Safety and Tolerability of Clobazam as Adjunctive Therapy in Paediatric Patients Aged ≥1 to ≤16 Years With Dravet Syndrome
|
Phase 3 |